Clinical Policy: Dasabuvir, Ombitasvir, Paritaprevir, Ritonavir (Viekira Pak)

Reference Number: GA.PMN.12
Effective Date: 12/16
Last Review Date: 7/2021
Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Dasabuvir/paritaprevir/ritonavir/ombitasvir (Viekira Pak™) is a combination of ombitasvir, a hepatitis C virus (HCV) NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor

FDA Approved Indication(s)
Viekira Pak is indicated for the treatment of adult patients with chronic HCV:
• Genotype 1b infection without cirrhosis or with compensated cirrhosis;
• Genotype 1a infection without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.

Policy/Criteria
It is the policy of health plans affiliated with Centene Corporation® that Viekira Pak is medically necessary when the following criteria are met:

I. Approval Criteria
**Provider must submit documentation (including office chart notes and lab results) supporting that member has met all approval criteria **

A. Chronic Hepatitis C Infection (must meet all):
1. Diagnosis of chronic hepatitis C virus (HCV) infection as evidenced by detectable serum HCV ribonucleic acid (RNA) levels by quantitative assay in the last 6 months;
2. Age ≥ 18 years;
3. Confirmed HCV genotype is 1;
   *Chart note documentation and copies of labs results are required
4. Member must use sofosvubir/velpatasvir (Epclusa®) (authorized generic preferred) or Mavyret®, unless both are contraindicated or clinically significant adverse effects are experienced; (see Appendix E);
5. If cirrhosis is present, confirmation of Child-Pugh A status;
6. Life expectancy ≥ 12 months with HCV treatment;
7. Prescribed regimen is consistent with an FDA or AASLD-IDSA recommended regimen (in Section III Dosage and Administration);
8. Member is hepatitis B virus (HBV) negative, or if positive, documentation that concurrent HBV infection is being treated (e.g., tenofovir alafenamide, adefovir, entecavir), unless contraindicated or clinically significant adverse effects are experienced (see Appendix E);

9. If HCV/human immunodeficiency virus (HIV)-1 co-infection, member is or will be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug resistance;

10. Dose does not exceed:
   a. For Viekira Pak: ombitasvir/paritaprevir/ritonavir 25 mg/150 mg/100 mg (2 tablets) once daily and dasabuvir 500 mg (1 tablet) twice daily;

11. Member has none of the following contraindications:
   a. Moderate to severe hepatic impairment (Child-Pugh B and C);
   b. Hypersensitivity to ritonavir (e.g., toxic epidermal necrolysis [TEN] or Stevens-Johnson syndrome);
   c. Co-administration with drugs that are highly dependent on cytochrome P450 (CYP) 3A for clearance, moderate or strong inducers of CYP3A, strong inducers of CYP2C8, and drugs that are strong inhibitors of CYP2C8 as follows: alfuzosin HCL, ranolazine, dronedarone, carbamazepine, phenytoin, phenobarbital, colchicine, gemfibrozil, rifampin, lurasidone, pimozone, ergotamine, dihydroergotamine, methylergonovine, ethinyl estradiol-containing medications such as combined oral contraceptives, cisapride, St. John’s Wort, lovastatin, simvastatin, efavirenz, sildenafil when dosed as Revatio for pulmonary arterial hypertension; triazolam, orally administered midazolam;
   d. If prescribed with ribavirin, member has none of the following contraindications:
      i. Pregnancy or possibility of pregnancy - member or partner;
      ii. Hypersensitivity to ribavirin;
      iii. Co-administration with didanosine;
      iv. Significant/unstable cardiac disease;
      v. Hemoglobinopathy (e.g., thalassemia major, sickle cell anemia);
      vi. Hemoglobin < 8.5 g/dL.

Approval duration: up to a total of 24 weeks*
(*Approved duration should be consistent with a regimen in in Section III Dosage and Administration)

B. Other diagnoses/indications: Refer to CP.PHAR.53 – No Coverage Criteria/Off-Label Use Policy if diagnosis is NOT listed in section I.

II. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

<table>
<thead>
<tr>
<th>Abbreviation/Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AASLD: American Association for the Study of Liver Diseases</td>
<td>MRE: magnetic resonance elastography</td>
</tr>
<tr>
<td>APRI: AST to platelet ratio</td>
<td>NS3/4A, NS5A/B: nonstructural protein</td>
</tr>
<tr>
<td>CTP: Child Turcotte Pugh</td>
<td>Peg-IFN: pegylated interferon</td>
</tr>
<tr>
<td>CrCl: creatinine clearance</td>
<td>PI: protease inhibitor</td>
</tr>
<tr>
<td>RBV: ribavirin</td>
<td></td>
</tr>
</tbody>
</table>
Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/ Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epclusa® (sofosbuvir/ velpatasvir)</td>
<td>Treatment-naïve or treatment-experienced with pegIFN/RBV without cirrhosis or with compensated cirrhosis: <strong>Genotype 1</strong> One tablet PO QD for 12 weeks</td>
<td>Epclusa: sofosbuvir 400 mg/ velpatasvir 100 mg (1 tablet) per day</td>
</tr>
<tr>
<td>Mavyret® (glecaprevir/ pibrentasvir)</td>
<td>Treatment-naïve: <strong>Genotype 1</strong> Without cirrhosis or with compensated cirrhosis: Three tablets PO QD for 8 weeks</td>
<td>Mavyret: glecaprevir 300 mg/pibrentasvir 120 mg (3 tablets) per day</td>
</tr>
<tr>
<td>Mavyret® (glecaprevir/ pibrentasvir)</td>
<td>Treatment-experienced with IFN/pegIFN + RBV +/- sofosbuvir: <strong>Genotype 1</strong> Without cirrhosis: Three tablets PO QD for 8 weeks With compensated cirrhosis: Three tablets PO QD for 12 weeks</td>
<td>Mavyret: glecaprevir 300 mg/pibrentasvir 120 mg (3 tablets) per day</td>
</tr>
</tbody>
</table>

*Therapeutic alternatives are listed as Brand Name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): Viekira Pak is contraindicated in:
  - Patients with moderate to severe hepatic impairment (Child-Pugh B and C) due to risk of potential toxicity
If Viekira is administered with RBV, the contraindications to RBV also apply to this combination regimen. Refer to the RBV prescribing information for a list of contraindications for RBV.

- Co-administration with drugs that are:
  - Highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events
  - Moderate or strong inducers of CYP3A and strong inducers of CYP2C8 and may lead to reduced efficacy of Viekira Pak
  - Strong inhibitors of CYP2C8 and may increase dasabuvir plasma concentrations and the risk of QT prolongation

- Patients with known hypersensitivity to ritonavir (e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome).
  - Boxed warning(s): risk of hepatitis B virus reactivation in patients coinfected with HCV and HBV

### Appendix D: Direct-Acting Antivirals for Treatment of HCV Infection

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Drug Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daklinza</td>
<td>Daclatasvir</td>
</tr>
<tr>
<td>Epclusa*</td>
<td>Velpatasvir Sofosbuvir</td>
</tr>
<tr>
<td>Harvoni*</td>
<td>Ledipasvir Sofosbuvir</td>
</tr>
<tr>
<td>Mavyret*</td>
<td>Pibrentasvir Glecaprevir</td>
</tr>
<tr>
<td>Sovaldi</td>
<td>Sofosbuvir</td>
</tr>
<tr>
<td>Viekira PAK*</td>
<td>Ombitasvir Dasabuvir Paritaprevir Ritonavir</td>
</tr>
<tr>
<td>Vosevi*</td>
<td>Velpatasvir Sofosbuvir Voxilaprevir</td>
</tr>
<tr>
<td>Zepatier*</td>
<td>Elbasvir Grazoprevir</td>
</tr>
</tbody>
</table>

*Combination drugs*

### Appendix E: General Information
- Acceptable medical justification for inability to use Mavyret (preferred product):
  o Drug-drug interactions with atazanavir
- Acceptable medical justification for inability to use Epclusa (preferred product):
  o In patients indicated for co-administration of Epclusa with ribavirin: contraindications to ribavirin
  o In patients indicated for co-administration with amiodarone: serious symptomatic bradycardia in patients taking amiodarone, with cardiac monitoring recommended.
- Hepatitis B Virus (HBV) Reactivation is a black box warning for all direct-acting antiviral drugs for the treatment of HCV. HBV reactivation has been reported when treating HCV for patients co-infected with HBV, leading to fulminant hepatitis, hepatic failure, and death, in some cases. Patients should be monitored for HBV reactivation and hepatitis flare during HCV treatment and post-treatment follow-up, with treatment of HBV infection as clinically indicated.
- For patients with HCV/HIV-1 (human immunodeficiency virus type-1) co-infection, the patient should be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug resistance.

### III. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 1a: Treatment-naive or treatment-experienced with pegIFN/RBV without cirrhosis</td>
<td>Viekira Pak plus weight-based RBV for 12 weeks</td>
<td>Viekira Pak: paritaprevir 150 mg /ritonavir 100mg/ ombitasvir 25 mg per day; dasabuvir 500 mg per day</td>
<td>FDA-approved labeling</td>
</tr>
<tr>
<td>Genotype 1b: Treatment-naïve or treatment-experienced with pegIFN/RBV with or without compensated cirrhosis</td>
<td>Viekira Pak for 12 weeks</td>
<td></td>
<td>FDA-approved labeling</td>
</tr>
</tbody>
</table>

*Note: AASLD/IDSA treatment guidelines for chronic hepatitis C infection are updated at irregular intervals; refer to the most updated AASLD/IDSA guideline for most accurate treatment regimen. The AASLD/IDSA HCV guidance updated September 2017 no longer recommends use of Viekira Pak for the treatment of genotype 1a with compensated cirrhosis.*

### IV. Product Availability

<table>
<thead>
<tr>
<th>Drug</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paritaprevir/ ritonavir/ ombitasvir/ dasabuvir (Viekira Pak)</td>
<td>Tablets: paritaprevir 75 mg, ritonavir 50 mg, ombitasvir 12.5 mg Tablets: dasabuvir 250 mg</td>
</tr>
</tbody>
</table>
V. References

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>New policy created, split from CP.PHAR.17 Hepatitis C Therapies. HCV RNA levels over six-month period added to confirm infection is chronic. Life expectancy “≥12 months if HCC and awaiting transplant” is modified to indicate “≥12 months with HCV therapy.” Testing criteria reorganized by “no cirrhosis”/”cirrhosis;” HCC population is included under “cirrhosis” and broadened to incorporate HCC amenable to curative measures (resection, ablation, transplant). Methods to diagnose fibrosis/cirrhosis are modified to require presence of HCC, liver biopsy or a combination of one serologic and one radiologic test. Serologic and radiologic tests are updated and correlated with METAVIR per Appendix B. Removed creatinine clearance restriction. Dosing regimens are presented in Appendix D and E per AASLD guidelines and FDA-approved indications. The initial approval period is shortened to 8 weeks.</td>
<td>08/16</td>
<td>09/16</td>
</tr>
<tr>
<td>Removed criteria regarding medication prescribed by a specialist</td>
<td>10/16</td>
<td>10/16</td>
</tr>
<tr>
<td>Remover criteria regarding having HCC or advanced liver disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Removed criteria regarding medication adherence program</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Removed criteria regarding sobriety from alcohol/illicit drugs</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Reviews, Revisions, and Approvals | Date | Approval Date
--- | --- | ---
Added availability of full course of therapy as initial therapy consistent with appendix recommendation for initial criteria Removed continuation criteria | 4/17 | 4/17
Added preferencing information requiring Mavyret for FDA-approved indications. Exception made to require Hep B screening for all patients prior to treatment. Added do not exceed dosing restrictions | 9/17 | 9/17
Annual review. No changes made. | 3/18 | 3/18
Changed current Georgia policy templates to corporate standard templates for drug coverage criteria to meet corporate compliance. Changes/revisions included; new formatting, font size, use of standard policy language for each section of policy, and rearranged order of certain steps in criteria and sections. Added new preferred treatment tables that includes dosage and frequency based on genotype for Mavyret. Removed background sections. Updated general information and contraindication section to be consistent with corporate HCV policies. | 2/21/19 | 2/19
Annual Review. Removed Viekira XR from policy as it was removed from the market 5/18. In the initial approval criteria, changed RNA detectable period from “over a 6 month period” to “in the last 6 months” for infection diagnosis. | 10/19 | 10/19
RT4: updated Mavyret dosing recommendations to 8 weeks total duration of therapy for treatment-naïve HCV with compensated cirrhosis across all genotypes (1-6). Added preferencing for AG Epclusa or Mavyret; removed redirection to Mavyret based on contraindications criteria; Removed Appendix D for Metavir scoring. Removed dosing for Mavyret treatment-naïve. Updated order of all other Appendices. Updated references. | 4/2020 | 4/2020
References reviewed and updated. | 7/2020 | 7/2020
Annual review. Added Mayvret and Vosevi to Appendix D-Direct Acting Antivirals for Treatment of HCV infection and removed Olysio, Technivie, and Viekira XR as these were previously removed from the market. Updated Appendix B: Therapeutic Alternatives dosing regimens. Changed Centene Logo to PSHP Logo. References reviewed and updated. | 4/2021 | 4/2021
Included reference to Appendix E with addition of contraindications that would warrant bypassing preferred agents; references reviewed and updated. | 7/2021 | 7/2021

**Important Reminder**
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical
information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note: For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained
herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.